EUVIMEDEUVIMED entdecken
Crossref

Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative

Whitney Seals, Mary Pat Holder, Shea Polancich, James Edward Bryant, Badari Birur, Bradley G Burk

American Journal of Health-System Pharmacy · 2024

DOI: 10.1093/ajhp/zxae196 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, 2024. Verfasst von Whitney Seals und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Alabama at Birmingham Medical Center, Birmingham, AL, USA. Hauptthemen laut MEDLINE: Benztropine, Quality Improvement, Antipsychotic Agents. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Secondary to the risk of antipsychotic-induced acute dystonia, prophylactic use of benztropine is occasionally warranted but is recommended for no longer than 7 days after initiating an antipsychotic, correlating to the period of highest dystonia risk. Despite the associated increased anticholinergic burden, many clinicians continue to order benztropine for periods exceeding the recommended prophylactic duration. We investigated the reduction of benztropine use duration subsequent to implementation of truncated electronic entry orders to improve benztropine prescribing within an acute psychiatric facility.

Methods

Data were collected for psychiatric inpatients admitted between January and June 2020 who were prescribed scheduled benztropine. In a quality improvement initiative implemented in April 2022, electronic orders for benztropine were modified from a 180-day to a 7-day duration, with subsequent postintervention data collection. The primary outcomes included a change in the duration of benztropine use for any indication in the hospital, and a change in the percentage of patients meeting predetermined “unnecessary use” criteria. Secondary analyses included the percentage of patients with discharge prescriptions for scheduled benztropine (either for prophylaxis or for other indications) in the pre- and postintervention periods.

Results

73 pre- and 77 postintervention individual patients/encounters were included. Following the intervention, in-hospital duration of benztropine use for any indication decreased from a median of 14 days to a median of 7.5 days (P < 0.05), and appropriate use increased by 92.9%. The percentage of patients with prescriptions for scheduled benztropine decreased from 67.1% in the preintervention group to 29.9% in the postintervention group.

Conclusion

Decreased benztropine use duration, by means of truncated order entry sentences, during inpatient psychiatric admissions, appears feasible regardless of dual antipsychotic or first-generation antipsychotic use, and may reduce the rates of benztropine prescriptions written for discharge.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenztropineQuality ImprovementAntipsychotic AgentsHumansMaleFemaleMiddle AgedAdultMental DisordersTime FactorsRetrospective Studies

Stichwörter der Autor:innen

EPSacute dystoniaanticholinergicbenztropineinpatient psychiatryprophylaxis

Substanzen

BenztropineAntipsychotic Agents

Autor:innen und Institutionen

  • Department of Pharmacy, University of Alabama at Birmingham Medical Center, Birmingham, AL, USA.
  • University of Alabama at Birmingham, School of Nursing, Birmingham, AL, USA.
  • Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL.
  • Department of Psychiatry, University of Alabama at Birmingham Medical Center, Birmingham, AL, USA.
  • Department of Pharmacy and Department of Psychiatry, University of Alabama at Birmingham Medical Center, Birmingham, AL.
  • Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham Heersink School of Medicine, Birmingham, AL, USA.

Zitieren

APA

Seals, W., Holder, M. P., Polancich, S., Bryant, J. E., Birur, B., & Burk, B. G. (2024). Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxae196

Vancouver

Seals W, Holder MP, Polancich S, Bryant JE, Birur B, Burk BG. Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative. American Journal of Health-System Pharmacy. 2024. doi:10.1093/ajhp/zxae196

BibTeX
@article{Seals2024,
  author = {Seals, Whitney and Holder, Mary Pat and Polancich, Shea and Bryant, James Edward and Birur, Badari and Burk, Bradley G},
  title = {Reduction of benztropine use duration in acute psychiatry: A quality improvement initiative},
  journal = {American Journal of Health-System Pharmacy},
  year = {2024},
  doi = {10.1093/ajhp/zxae196}
}
Kostenlos starten →